News | June 28, 2022
Balaxi Pharmaceuticals' Hyderabad factory to be operational by March 2024
This facility will produce higher efficacy products that enjoy greater acceptance and enhanced profit marginsg
This facility will produce higher efficacy products that enjoy greater acceptance and enhanced profit marginsg
Revenues from operations for the full year ended March 31, 2022 stood at Rs. 590.05 crore as compared to Rs. 449.82 crore in FY21
This agreement is in addition to the $92 million filling line expansion announced in November 2021
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
Bionova Scientific’s process development capabilities are particularly highly regarded in the industry, and it has a rich track record regarding complex next-generation antibody drugs, which are typically challenging to manufacture
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
The plant is scheduled to come on stream in September 2024
The company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
Subscribe To Our Newsletter & Stay Updated
